The development of targeted anti-cancer therapeutics offers the potential for increased efficacy of drugs and diagnostics. Utilizing modalities agnostic to tumor type, such as the hypoxic tumor microenvironment (TME), may assist in the development of universal tumor targeting agents. The hypoxia-inducible factor (HIF), in particular HIF1, plays a key role in tumor adaptation to hypoxia, and inhibiting its interaction with p300 has been shown to provide therapeutic potential. Using a multivalent assembled protein (MAP) approach based on the self-assembly of the cartilage oligomeric matrix protein coiled-coil (COMPcc) domain fused to the critical residues of the C-terminal transactivation domain (C-TAD) of the α subunit of HIF1 (HIF1α), we generate HIF1α-MAP (H-MAP). The resulting H-MAP demonstrates picomolar binding affinity to p300, the ability to downregulate hypoxia-inducible genes, and tumor targeting capability.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191652PMC
http://dx.doi.org/10.1039/d4bm00354cDOI Listing

Publication Analysis

Top Keywords

tumor targeting
8
tumor
5
engineered coiled-coil
4
coiled-coil hif1α
4
hif1α protein
4
protein domain
4
domain mimic
4
mimic development
4
development targeted
4
targeted anti-cancer
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!